Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Nuria Muñoz‐Rivas, Jesús Aibar, Cristina Gabara-Xancó, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5632-5632
Open Access | Times Cited: 18

Showing 18 citing articles:

2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Sam Schulman, Donald M. Arnold, Charlotte Bradbury, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 6, pp. 1779-1797
Open Access | Times Cited: 18
Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia
Vincent Labbé, Damien Contou, Nicholas Heming, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 6, pp. 520-520
Open Access | Times Cited: 21
Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient and post-discharge prophylaxis: a meta-analysis of randomized controlled trials
Jiahao Meng, Hang Tang, Yifan Xiao, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 8
Therapeutic Versus Non‐Therapeutic Dose Anticoagulation in COVID‐19 Infection: A Systematic Review and Meta‐analysis of Randomised Controlled Trials
Sushil Selvarajan, Jisha Sara John, Prathap Tharyan, et al.
eJHaem (2025) Vol. 6, Iss. 1
Open Access
Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry
Crhistian‐Mario Oblitas, Pablo Demelo-Rodríguez, Lucía Barrera-López, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Predictors of venous thromboembolic events in hospitalized patients with COVID-19
Giovanni Scimeca, Darsiya Krishnathasan, Sina Rashedi, et al.
Journal of Thrombosis and Thrombolysis (2025)
Closed Access
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
Stéphane Zuily, Benjamin Lefèvre, Olivier Sanchez, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102031-102031
Open Access | Times Cited: 13
The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies
Eros Pilia, Alessandro Belletti, Stefano Fresilli, et al.
Lung (2023) Vol. 201, Iss. 2, pp. 135-147
Open Access | Times Cited: 10
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis
Stefanie Reis, Amon Faske, Ina Monsef, et al.
Thrombosis Research (2024) Vol. 238, pp. 141-150
Open Access | Times Cited: 3
Comparative analysis of COVID-19-associated venous thromboembolism outcomes: evolution from 2020 to 2021–2022
Francisco Galeano‐Valle, Pablo Demelo-Rodríguez, Rubén Alonso-Beato, et al.
Journal of Thrombosis and Thrombolysis (2024) Vol. 57, Iss. 7, pp. 1239-1248
Closed Access | Times Cited: 2
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)
Laura Ortega, Francisco José Pelegrín Mateo, Rut Porta Balanyà, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 11, pp. 2877-2901
Open Access | Times Cited: 2
Anticoagulation Among Patients Hospitalized for COVID-19
Claire L. Vale, Peter J. Godolphin, David J. Fisher, et al.
Annals of Internal Medicine (2024)
Closed Access | Times Cited: 1
Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis
Awatif Hafiz, Hadeel Alkofide, Khalid Al Sulaiman, et al.
Clinical and Applied Thrombosis/Hemostasis (2023) Vol. 29
Open Access | Times Cited: 2
Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials
Javier Ena, Victoria Valls
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 4, pp. 1189-1196
Open Access | Times Cited: 4
Thrombotic Long-Term Consequences of SARS-CoV-2 Infection in Patients with Compensated Cirrhosis: A Propensity Score-Matched Analysis of a U.S. Database
Mark Ayoub, Carol Faris, Tajana Juranovic, et al.
Diseases (2024) Vol. 12, Iss. 7, pp. 161-161
Open Access
Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia
Juan Mora-Delgado, Cristina Lojo-Cruz, Patricia Rubio, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 928-928
Open Access | Times Cited: 1
Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis
Emőke Henrietta Kovács, Krisztián Tánczos, L. Szabó, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2194-2194
Open Access | Times Cited: 1
Antithrombotic therapy in the management of hospitalised patients with COVID-19
Ioannis Koulas, Mark Goldin, Sam Schulman, et al.
British Journal of Hospital Medicine (2023) Vol. 84, Iss. 5, pp. 1-11
Closed Access
Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond
Michael Dalager‐Pedersen
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 9, pp. 1184-1186
Open Access
Page 1

Scroll to top